Abstract：
BACKGROUND: Chronic Hand Eczema (CHE) is a heterogeneous fluctuating inflammatory disease that represents a significant burden. Effective treatment options for moderate to severe CHE are limited.
OBJECTIVE: To assess how patients with moderate to severe CHE are treated in clinical practice.
METHODS: A retrospective, physician-led patient record review assessed the demographic, clinical and treatment characteristics of patients aged ≥18 years with CHE across seven countries. Each participating physician was requested to review records for their three most recent patients with moderate to severe CHE treated with a topical or systemic therapy.
RESULTS: A total of 264 physicians, of whom 88.6% were dermatologists and 70.1% were predominantly or partly hospital-based, reviewed the records of 792 patients. Signs were present on hands only in 56.4% of patients and the mean time on current treatment was 16.7 months. Overall, 62.9% of patients received systemic therapy and almost one-quarter (23.4%) were treated with a biologic; 28.6% of patients were only treated with topical corticosteroids and/or topical calcineurin inhibitors.
CONCLUSIONS: In patients with moderate to severe CHE, most received systemic therapy with one-quarter on biologic therapy. However, given that many of these treatments have limited evidence of efficacy in CHE, there is a need for studies specifically in patients with CHE as well as new therapeutic options.
OBJECTIVE: To assess how patients with moderate to severe CHE are treated in clinical practice.
METHODS: A retrospective, physician-led patient record review assessed the demographic, clinical and treatment characteristics of patients aged ≥18 years with CHE across seven countries. Each participating physician was requested to review records for their three most recent patients with moderate to severe CHE treated with a topical or systemic therapy.
RESULTS: A total of 264 physicians, of whom 88.6% were dermatologists and 70.1% were predominantly or partly hospital-based, reviewed the records of 792 patients. Signs were present on hands only in 56.4% of patients and the mean time on current treatment was 16.7 months. Overall, 62.9% of patients received systemic therapy and almost one-quarter (23.4%) were treated with a biologic; 28.6% of patients were only treated with topical corticosteroids and/or topical calcineurin inhibitors.
CONCLUSIONS: In patients with moderate to severe CHE, most received systemic therapy with one-quarter on biologic therapy. However, given that many of these treatments have limited evidence of efficacy in CHE, there is a need for studies specifically in patients with CHE as well as new therapeutic options.
摘要：
背景：慢性手部湿疹（CHE）是一种异质性波动的炎症性疾病，具有很大的负担。中度至重度CHE的有效治疗选择有限。
目的：评估在临床实践中如何治疗中度至重度CHE患者。
方法：回顾性研究，由医生主导的患者记录审查评估了人口统计，7个国家年龄≥18岁CHE患者的临床和治疗特征。每位参与的医生被要求审查他们最近三名接受局部或全身治疗的中度至重度CHE患者的记录。
结果：共有264名医生，其中88.6%是皮肤科医生，70.1%主要或部分是医院医生，回顾了792例患者的记录。仅56.4％的患者出现体征，当前治疗的平均时间为16.7个月。总的来说,62.9％的患者接受了全身治疗，近四分之一（23.4％）接受了生物制剂治疗；28.6％的患者仅接受了局部皮质类固醇和/或局部钙调磷酸酶抑制剂治疗。
结论：在中度至重度CHE患者中，大多数人接受了全身性治疗,其中四分之一接受了生物治疗.然而,鉴于这些治疗方法中的许多在CHE中的疗效证据有限，需要专门针对CHE患者的研究以及新的治疗选择.
目的：评估在临床实践中如何治疗中度至重度CHE患者。
方法：回顾性研究，由医生主导的患者记录审查评估了人口统计，7个国家年龄≥18岁CHE患者的临床和治疗特征。每位参与的医生被要求审查他们最近三名接受局部或全身治疗的中度至重度CHE患者的记录。
结果：共有264名医生，其中88.6%是皮肤科医生，70.1%主要或部分是医院医生，回顾了792例患者的记录。仅56.4％的患者出现体征，当前治疗的平均时间为16.7个月。总的来说,62.9％的患者接受了全身治疗，近四分之一（23.4％）接受了生物制剂治疗；28.6％的患者仅接受了局部皮质类固醇和/或局部钙调磷酸酶抑制剂治疗。
结论：在中度至重度CHE患者中，大多数人接受了全身性治疗,其中四分之一接受了生物治疗.然而,鉴于这些治疗方法中的许多在CHE中的疗效证据有限，需要专门针对CHE患者的研究以及新的治疗选择.
